2月2日——生物技术公司PYC Therapeutics Ltd公布新一轮融资方案，计划以每股1.50澳元的价格募集最高达6.53亿澳元资金。此次融资将用于推进公司创新疗法管线的临床开发。作为澳大利亚证券交易所上市公司，PYC Therapeutics专注于开发针对遗传性眼病和癌症的RNA靶向疗法。该融资方案预计将增强公司的资本结构，为后续临床试验提供资金支持。
2月2日——生物技术公司PYC Therapeutics Ltd公布新一轮融资方案，计划以每股1.50澳元的价格募集最高达6.53亿澳元资金。此次融资将用于推进公司创新疗法管线的临床开发。作为澳大利亚证券交易所上市公司，PYC Therapeutics专注于开发针对遗传性眼病和癌症的RNA靶向疗法。该融资方案预计将增强公司的资本结构，为后续临床试验提供资金支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.